Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA

被引:592
作者
Ryo, A
Suizu, F
Yoshida, Y
Perrem, K
Liou, YC
Wulf, G
Rottapel, R
Yamaoka, S
Lu, KP
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Canc Biol Program,Div Hematol Oncol,Dept Med, Boston, MA 02215 USA
[2] Yokohama City Univ, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[3] Univ Occupat & Environm Hlth, Dept Immunol, Yahata Nishi Ku, Fukuoka 8078555, Japan
[4] Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada
[5] Tokyo Med & Dent Univ, Dept Mol Virol, Bunkyo Ku, Tokyo 1138519, Japan
关键词
D O I
10.1016/S1097-2765(03)00490-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The transcription factor NF-kappaB is activated by the degradation of its inhibitor IB, resulting in its nuclear translocation. However, the mechanism by which nuclear NF-kappaB is subsequently regulated is not clear. Here we demonstrate that NF-kappaB function is regulated by Pin1-mediated prolyl isomerization and ubiquitin-mediated proteolysis of its p65/RelA subunit. Upon cytokine treatment, Pin1 binds to the pThr254-Pro motif in p65 and inhibits p65 binding to IkappaBalpha, resulting in increased nuclear accumulation and protein stability of p65 and enhanced NF-kappaB activity. Significantly, Pin1-deficient mice and cells are refractory to NF-kappaB activation by cytokine signals. Moreover, the stability of p65 is controlled by ubiquitin-mediated proteolysis, facilitated by a cytokine signal inhibitor, SOCS-1, acting as a ubiquitin ligase. These findings uncover two important mechanisms of regulating NF-kappaB signaling and offer new insight into the pathogenesis and treatment of some human diseases such as cancers.
引用
收藏
页码:1413 / 1426
页数:14
相关论文
共 44 条
[1]  
AYALA G, 2003, CANCER RES, V4, P175
[2]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[3]   The Fas-associated death domain protein suppresses activation of NF-κB by LPS and IL-1β [J].
Bannerman, DD ;
Tupper, JC ;
Kelly, JD ;
Winn, RK ;
Harlan, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :419-425
[4]   EMBRYONIC LETHALITY AND LIVER DEGENERATION IN MICE LACKING THE RELA COMPONENT OF NF-KAPPA-B [J].
BEG, AA ;
SHA, WC ;
BRONSON, RT ;
GHOSH, S ;
BALTIMORE, D .
NATURE, 1995, 376 (6536) :167-170
[5]   Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells [J].
Bhat-Nakshatri, P ;
Sweeney, CJ ;
Nakshatri, H .
ONCOGENE, 2002, 21 (13) :2066-2078
[6]   Nuclear Factor-KB (NF-KB) regulates proliferation and branching in mouse mammary epithelium [J].
Brantley, DM ;
Chen, CL ;
Muraoka, RS ;
Bushdid, PB ;
Bradberry, JL ;
Kittrell, F ;
Medina, D ;
Matrisian, LA ;
Kerr, LD ;
Yull, FE .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (05) :1445-1455
[7]   IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development [J].
Cao, YX ;
Bonizzi, G ;
Seagroves, TN ;
Greten, FR ;
Johnson, R ;
Schmidt, EV ;
Karin, M .
CELL, 2001, 107 (06) :763-775
[8]   Hepatocyte-specific inhibition of NF-κB leads to apoptosis after TNF treatment, but not after partial hepatectomy [J].
Chaisson, ML ;
Brooling, JT ;
Ladiges, W ;
Tsai, S ;
Fausto, N .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (02) :193-202
[9]   Duration of nuclear NF-κB action regulated by reversible acetylation [J].
Chen, LF ;
Fischle, W ;
Verdin, E ;
Greene, WC .
SCIENCE, 2001, 293 (5535) :1653-1657
[10]  
DADD CA, 1993, BIOTECHNIQUES, V14, P266